Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer

doi:10.1053/j.gastro.2009.11.005

Gastroenterology

Volume 138, Issue 3, March 2010, Pages 958-968

, , , , , , , , , , , , , , , , , ,

https://doi.org/10.1053/j.gastro.2009.11.005 Get rights and content

Background & aims

Staging inadequately predicts metastatic risk in patients with colon cancer. We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence.

Methods

This phase 1, exploratory biomarker study used 55 patients with colorectal cancer from Vanderbilt Medical Center (VMC) as the training dataset and 177 patients from the Moffitt Cancer Center as the independent dataset. The metastasis-associated gene expression profile developed from the mouse model was refined with comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer. A metastasis score derived from the biologically based classifier was tested in the Moffitt dataset.

Results

A high score was significantly associated with increased risk of metastasis and death from colon cancer across all pathologic stages and specifically in stage II and stage III patients. The metastasis score was shown to independently predict risk of cancer recurrence and death in univariate and multivariate models. For example, among stage III patients, a high score translated to increased relative risk of cancer recurrence (hazard ratio, 4.7; 95% confidence interval, 1.566–14.05). Furthermore, the metastasis score identified patients with stage III disease whose 5-year recurrence-free survival was >88% and for whom adjuvant chemotherapy did not increase survival time.

Conclusion

A gene expression profile identified from an experimental model of colon cancer metastasis predicted cancer recurrence and death, independently of conventional measures, in patients with colon cancer.

Section snippets

Cell Culture and Mouse Model

MC-38 mouse adenocarcinoma cells were obtained from the American Type Culture Collection (Manassas, VA).⁹ MC-38 cells were transfected with firefly luciferase gene (pGL3 basic; Promega, Madison, WI) and selected (G418; Invitrogen, Carlsbad, CA). To enrich for invasive cells, 7.5 × 10⁵ cells were seeded onto 6-well, 8.0-micron pore transwell polycarbonate membrane inserts (Costar, Cambridge, MA) coated with 2.5 mg/mL matrigel, and incubated with serum-free Dulbecco's modified Eagle's medium in

Development of an Immunocompetent Mouse Model of Colon Cancer Metastasis

Tumors are a heterogeneous mixture of cells with varied invasive and metastatic potentials. Therefore, we used a conventional invasion assay to enrich for a subpopulation of highly invasive MC-38 mouse colon cancer cells (Figure 1A, MC-38inv). After 6 serial passages through matrigel, MC-38inv cells were more invasive than MC-38 parental cells both in vitro and in vivo in a tail vein injection assay (Figure 1B and Supplementary Table 1; P < .001). Lung tumors derived from MC-38inv cells were

Discussion

In the present study, the biology of colon cancer metastasis was modeled in immunocompetent mice to develop a gene expression classifier that discriminates recurrence and survival outcomes in human patients with colon cancer. Patients with stage II and stage III primary colon cancers that reflected the recurrence-associated gene expression pattern were at greater relative risk of recurrence than patients who did not (HR = 13.1 and 4.7, respectively). This gene expression profile, tested with a

Acknowledgments

The authors thank James Goldenring, MD, PhD, Eric Neilson, MD, and Vivien Siegel, PhD for critically reviewing the manuscript in advance of submission. We thank Ramona Deal for derivation of luciferase-expressing MC-38 parental cells. We thank the Vanderbilt Microarray Shared Resource. We gratefully acknowledge the generous philanthropic support of the Ingram family. J.J.S. gratefully acknowledges support from the Society of University Surgeons-Ethicon Scholarship Award, the Vanderbilt Clinical

References (35)

J.C. Wu et al.
Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice
Mol Ther
(2001)
J.S. Lee et al.
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets
Gastroenterology
(2004)
J.W. Tukey
Tightening the clinical trial
Control Clin Trials
(1993)
K. Yanagisawa et al.
Proteomic patterns of tumour subsets in non-small-cell lung cancer
Lancet
(2003)
D. Wang et al.
Pro-inflammatory prostaglandins and progression of colorectal cancer
Cancer Lett
(2008)
A. Jemal et al.
Cancer statistics, 2008
CA Cancer J Clin
(2008)
P. Ragnhammar et al.
A systematic overview of chemotherapy effects in colorectal cancer
Acta Oncol
(2001)
A.B. Benson et al.
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
J Clin Oncol
(2004)
S. Gill et al.
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
J Clin Oncol
(2004)
E. Mamounas et al.
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
J Clin Oncol
(1999)

R. Gray et al.

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study

Lancet

(2007)

A. Figueredo et al.

Adjuvant therapy for completely resected stage II colon cancer

Cochrane Database Syst Rev

(2008)

A. Figueredo et al.

Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group

J Clin Oncol

(2004)

R. Lafreniere et al.

A novel approach to the generation and identification of experimental hepatic metastases in a murine model

J Natl Cancer Inst

(1986)

G. Poste et al.

Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells

Proc Natl Acad Sci U S A

(1981)

I.J. Fidler et al.

Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines

J Natl Cancer Inst

(1976)

D.E. Jenkins et al.

Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis

Clin Exp Metastasis

(2003)

Cited by (561)

Triacanthine enhances the sensitivity of colorectal cancer cells to 5-fluorouracil by regulating RRM2
2024, Phytomedicine
According to the literatures, triacanthine is isolated from the leaves of Gleditsia triacanthos L. and acts as an anti-hypertensive agent, also cardiotonic, antispasmodic and a respiratory analeptic. The 5-fluorouracil (5-FU) is widely used to treat the patients of colorectal cancer (CRC), but the resistance to 5-FU treatment restricts the therapeutic efficacy of CRC patients.
This study aims to explore a novel therapeutics regimen overcoming CRC resistance to 5-FU.
The cell proliferation of CRC cells was determined by SRB and colony formation assay. Transwell and wound-healing assay were applied to explore the potential metastatic abilities of CRC cells. qRT-PCR and Western blot were performed to evaluate the level of indicated mRNAs and proteins respectively. Xenograft assay was used to explore the anti-CRC effect of triacanthine.
Triacanthine statistically restrained CRC proliferation both in vitro and in vivo. Triacanthine induced cell cycle G1/G0 phase arrest in CRC cells. Meanwhile, triacanthine also inhibited the migrative and invasive abilities of CRC cells. A Venn diagram was generated showing that O-6-Methylguanine-DNA Methyltransferase (MGMT) might be a molecular target of triacanthine in treating CRC. Furthermore, triacanthine plus 5-FU significantly suppressed the cell proliferation of CRC cells compared with single agent treatment alone, and highly synergistic anti-cancer effects were scored when 5-FU was combined with triacanthine in CRC cells. In addition, triacanthine sensitized the anti-cancer activity of 5-FU via regulating Ribonucleotide Reductase Regulatory Subunit M2 (RRM2). MGMT or RRM2 might be novel biomarkers for evaluating the therapeutical efficiency of 5-FU in CRC patients.
We firstly demonstrated triacanthine suppressed cell proliferation and metastasis abilities and found the novel molecular targets of triacanthine in CRC cells. This is the first study to evaluate the anti-cancer efficiency of triacanthine plus 5-FU. Our study has revealed triacanthine as a pertinent sensitizer to 5-FU, and provided novel strategies for predicting outcomes and reversing resistance of 5-FU therapy.
Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells
2024, Immunity
RNA splicing is involved in cancer initiation and progression, but how it influences host antitumor immunity in the metabolically abnormal tumor microenvironment (TME) remains unclear. Here, we demonstrate that lactate modulates Foxp3-dependent RNA splicing to maintain the phenotypic and functional status of tumor-infiltrating regulatory T (Treg) cells via CTLA-4. RNA splicing in Treg cells was correlated with the Treg cell signatures in the TME. Ubiquitin-specific peptidase 39 (USP39), a component of the RNA splicing machinery, maintained RNA-splicing-mediated CTLA-4 expression to control Treg cell function. Mechanistically, lactate promoted USP39-mediated RNA splicing to facilitate CTLA-4 expression in a Foxp3-dependent manner. Moreover, the efficiency of CTLA-4 RNA splicing was increased in tumor-infiltrating Treg cells from patients with colorectal cancer. These findings highlight the immunological relevance of RNA splicing in Treg cells and provide important insights into the environmental mechanism governing CTLA-4 expression in Treg cells.
Coiled-coil domain-containing 154 promotes colorectal cancer proliferation and metastasis via interacting with minichromosome maintenance complex component 2
2023, Cancer Letters
Coiled-Coil Domain-Containing (CCDC) is a large class of structural proteins containing left-handed supercoiled structure. The clinical value and the functional implication of CCDC in colorectal cancer (CRC) remain unknown. Based on the genetic, transcriptional, and clinical data from The Cancer Genome Atlas, five of thirty-six CCDC proteins were differentially expressed in the CRC and associated with the survival of patients with CRC. A CCDC-score model was established to evaluate the prognosis of patients. The potential function of Coiled-Coil Domain-Containing 154 (CCDC154) was investigated using bioinformatical methods, which unveiled that high expression of CCDC154 indicates poor survival for patients with CRC and correlates with low infiltration of CD8⁺ T cells and high infiltration of neutrophils, indicating that CCDC154 enhances tumor growth and metastasis. CCDC154 interacts with Minichromosome Maintenance Complex Component 2 (MCM2) protein and promotes malignant phenotype via MCM2. We validated the expression level and survival prediction value of CCDC154 in clinical samples, and analyzed its co-expression of MCM2, Ki-67 and p53. This work discloses the role of CCDC in clinical setting and CCDC154 functions in CRC.
Development and validation of an artificial intelligence prediction model and a survival risk stratification for lung metastasis in colorectal cancer from highly imbalanced data: A multicenter retrospective study
2023, European Journal of Surgical Oncology
To assist clinicians with diagnosis and optimal treatment decision-making, we attempted to develop and validate an artificial intelligence prediction model for lung metastasis (LM) in colorectal cancer (CRC) patients.
The clinicopathological characteristics of 46037 CRC patients from the Surveillance, Epidemiology, and End Results (SEER) database and 2779 CRC patients from a multi-center external validation set were collected retrospectively. After feature selection by univariate and multivariate analyses, six machine learning (ML) models, including logistic regression, K-nearest neighbor, support vector machine, decision tree, random forest, and balanced random forest (BRF), were developed and validated for the LM prediction. In addition, stratified LM patients by risk score were utilized for survival analysis.
Extremely low rates of LM with 2.59% and 4.50% were present in the development and validation set. As the imbalanced learning strategy, the BRF model with an Area under the receiver operating characteristic curve (AUC) of 0.874 and an average precision (AP) of 0.184 performed best compares with other models and clinical predictor. Patients with LM in the high-risk group had significantly poorer survival (P＜0.001) and failed to benefit from resection (P = 0.125).
In summary, we have utilized the BRF algorithm to develop an effective, non-invasive, and practical model for predicting LM in CRC patients based on highly imbalanced datasets. In addition, we have implemented a novel approach to stratify the survival risk of CRC patients with LM based the output of the model.
AXL transcriptionally up-regulates TMEM14A expression to mediate cell proliferation in non-small-cell lung cancer cells
2023, Biochemical and Biophysical Research Communications
In non-small cell lung cancer (NSCLC), the receptor tyrosine kinase AXL has been identified as a potent activator of tumor progression and resistance to therapies. However, the molecular mechanisms behind AXL-mediated oncogenesis remain elusive. Current study thus aimed to uncover potential downstream genes regulated by AXL in NSCLC. Through transcriptomic RNA sequencing of AXL-silenced NSCLC cells, TMEM14A was identified as a significantly up-regulated gene. Clinical evaluations using GEPIA2 revealed that TMEM14A mRNA expression was notably higher in lung adenocarcinoma (LUAD) tumor tissues compared to normal tissues. Further, significantly increased TMEM14A levels were associated with poorer overall survival in LUAD patients. Experimentally, silencing TMEM14A in NSCLC cells led to reduced cellular proliferation and ATP levels, highlighting a key role of TMEM14A in NSCLC progression. Moreover, our promoter analysis demonstrated that AXL-mediated regulation of TMEM14A transcription could involve binding of transcription factors STAT and NF-κB to 5′-promoter of TMEM14A. Collectively, current study unveils TMEM14A as a novel downstream target of AXL, suggesting its potential as a therapeutic target to counteract resistance in future NSCLC patients undergoing AXL-targeted therapies.
Identification and validation of a novel six-gene signature based on mucinous adenocarcinoma-related gene molecular typing in colorectal cancer
2024, Discover Oncology

View all citing articles on Scopus

: The current address for Fei Wu is Bureau of Communicable Disease and Prevention, Missouri Department of Health and Senior Services, 930 Wildwood, PO Box 570, Jefferson City, Missouri 65102. The current address for Carl Schmidt is The Ohio State University Medical Center, College of Medicine, Division of Surgical Oncology, N-924 Doan Hall, 410 West 10th Avenue, Columbus, OH 43210-1240.

: GEO accession number is GSE17538. Complete Minimum information about a microarray experiment (MIAME)-compliant datasets for analysis is available (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17538).

: Conflicts of interest The authors disclose no conflicts.

: Funding This work was supported by the following grants from the National Institutes of Health: CA69457, DK52334, CA068485, and CA077839 (R.D.B.); TL1 RR024978 and CA106183 (J.J.S.); CA46413, CA95103, and CA084239 (R.J.C.); CA112215 (T.J.Y.); and CA126588 and CA128323 (N.G.D.). Other sources of funding include the Society of University Surgeons-Ethicon Scholarship Award (J.J.S.).

: J. Joshua Smith, Natasha G. Deane, Fei Wu, and R. Daniel Beauchamp contributed equally to this work.

View full text

Basic—Alimentary TractExperimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer

Background & aims

Methods

Results

Conclusion

Section snippets

Cell Culture and Mouse Model

Development of an Immunocompetent Mouse Model of Colon Cancer Metastasis

Discussion

Acknowledgments

Mol Ther

Gastroenterology

Control Clin Trials

Lancet

Cancer Lett

Cancer statistics, 2008

CA Cancer J Clin

A systematic overview of chemotherapy effects in colorectal cancer

Acta Oncol

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

J Clin Oncol

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

J Clin Oncol

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

J Clin Oncol

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study

Lancet

Adjuvant therapy for completely resected stage II colon cancer

Cochrane Database Syst Rev

Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group

J Clin Oncol

A novel approach to the generation and identification of experimental hepatic metastases in a murine model

J Natl Cancer Inst

Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells

Proc Natl Acad Sci U S A

Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines

J Natl Cancer Inst

Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis

Clin Exp Metastasis

Basic—Alimentary Tract
Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer